Jordyn Sava is an editor for Targeted Oncology.
Nivolumab/Ipilimumab Continues to Show OS Benefit in NSCLC at 6 Years
September 18th 2023With a minimum of 73.5 months of follow-up, nivolumab plus ipilimumab showed a benefit in overall survival in patients with treatment-naive stage IV or recurrent non–small cell lung cancer with no known EGFR/ALK alterations.
FDA Receives Rolling NDA of Tovorafenib for Pediatric Low-Grade Glioma
September 14th 2023Data from the phase 2 FIREFLY-1 trial support the new drug application for tovorafenib in relapsed or progressive pediatric low-grade glioma. The regulatory agency anticipates filing the application by mid-November 2023
Ivaltinostat Combinations Show Promise for Pancreatic Adenocarcinoma
September 13th 2023In an interview, Mohamad Adham Salkeni, MD, FRCPC, discussed the ongoing study of maintenance ivaltinostat plus capecitabine or capecitabine monotherapy in patients with metastatic pancreatic adenocarcinoma whose disease has not progressed on first-line FOLFIRINOX.
Furmonertinib Shows Encouraging Efficacy in EGFR Exon20Ins Mut+ NSCLC
September 10th 2023According to Baohui Han, MD, PhD, the confirmed objective response rate was 78.6% for treatment-naïve patients with non–small cell lung cancer with EGFR Exon20 insertion mutations treated with furmonertinib 240 mg daily in the FAVOUR trial.
Quizartinib Improves OS in Multiple FLT3-ITD+ AML Subgroups
September 9th 2023According to a presentation at SOHO 2023, overall survival was boosted among patients from the QuANTUM-First trial who went to transplant in first remission and were treated with quizartinib for their FLT3-ITD-positive acute myeloid leukemia.
FDA Gives Direction for BLA Resubmission of Denileukin Diftitox in CTCL
September 8th 2023Guidance from the FDA has provided a clear pathway and requested no additional efficacy or safety trials for the resubmission of the biologics license application for denileukin diftitox in cutaneous T-cell lymphoma.
Potential Need to Update Recommendations for CNS Prophylaxis in ALL
September 7th 2023With the emergence of tyrosine kinase inhibitors and targeted immunotherapies in the front line, outcomes for patients with ALL have improved. However, questions about central nervous system involvement and prophylaxis persist.
Phase 2 of ARROS-1 Trial Assessing NVL-520 in Solid Tumors Commences
September 5th 2023As determined by phase 1 of the ARROS-1 study, patients with ROS1-positive non–small cell lung cancer and other solid tumors will be further assessed with the recommended phase 2 dose of NVL-520 in phase 2 of the trial.